These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2481786)

  • 21. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure.
    Packer M; Lee WH; Kessler PD; Gottlieb SS; Bernstein JL; Kukin ML
    Circulation; 1987 May; 75(5 Pt 2):IV80-92. PubMed ID: 2882867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels.
    Mayer B; Holmer SR; Hengstenberg C; Lieb W; Pfeifer M; Schunkert H
    Int J Cardiol; 2005 Aug; 103(2):182-6. PubMed ID: 16080978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Critical analysis of beta blockers in heart failure: certainty and incompleteness].
    Rapezzi C; Branzi A
    Ital Heart J Suppl; 2000 Aug; 1(8):1003-10. PubMed ID: 10993006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are we misunderstanding beta-blockers.
    Cruickshank JM
    Int J Cardiol; 2007 Aug; 120(1):10-27. PubMed ID: 17433471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Beta-blockers and heart failure].
    Lechat P
    Therapie; 1994; 49(3):219-24. PubMed ID: 7878587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recent advances and limitations of medical treatment on heart failure].
    Momomura S
    Kyobu Geka; 2007 Jun; 60(6):484-7. PubMed ID: 17564066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Beta-blockers in cardiac insufficiency: should they always be considered in the therapeutic strategy? Arguments against].
    Ortigosa Aso J; Silva Melchor L; García A; de Artaza Andrade M
    Rev Esp Cardiol; 1997 May; 50(5):304-7. PubMed ID: 9281008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction between cardiac sympathetic drive and heart rate in heart failure: modulation by adrenergic receptor genotype.
    Kaye DM; Smirk B; Finch S; Williams C; Esler MD
    J Am Coll Cardiol; 2004 Nov; 44(10):2008-15. PubMed ID: 15542284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta blocker treatment in heart failure.
    Carson PE
    Prog Cardiovasc Dis; 1999; 41(4):301-21. PubMed ID: 10362350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-receptor-active agents: role of partial agonists in patients with heart failure.
    Franciosa JA
    J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S44-7. PubMed ID: 2478809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of cardiac insufficiency by beta-blockaders. A review of the literature and discussion].
    Hermida JS; Jarry G; Bertrand S; Guillaumont MP; Rey JL; Bernasconi P
    Ann Cardiol Angeiol (Paris); 1990 Feb; 39(2):103-7. PubMed ID: 1970467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mechanisms and consequences of changes of the vasomotor activity in cardiac insufficiency].
    Thuillez C; Annane D
    Arch Mal Coeur Vaiss; 1991 Jan; 84 Spec No 1():65-8. PubMed ID: 2053835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group.
    Witchitz S; Cohen-Solal A; Dartois N; Weisslinger N; Juste K; Darmon JY
    Am J Cardiol; 2000 Jun; 85(12):1467-71. PubMed ID: 10856394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Synopsis of endocrine and hemodynamic changes in heart failure].
    Wedler B
    Z Kardiol; 1991; 80 Suppl 8():53-6. PubMed ID: 1796635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sympathetic activation in heart failure: A target of therapeutic approaches.
    Schnabel P; Böhm M
    Z Kardiol; 1999 Oct; 88(Suppl 3):S005-11. PubMed ID: 27320303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New pathogenic findings on the mechanism of heart failure and their importance in therapy].
    Dúbrava J; Cagán S
    Vnitr Lek; 1992 Nov; 38(11):1119-26. PubMed ID: 1494878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of Beta-Blockers Action in Patients with Heart Failure.
    Prijic S; Buchhorn R
    Rev Recent Clin Trials; 2014; 9(2):58-60. PubMed ID: 25198736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Required beta blocker profile in the elderly.
    Opie LH
    Cardiovasc Drugs Ther; 1991 Jan; 4 Suppl 6():1273-80. PubMed ID: 1672603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Perioperative beta-blockers. Part one: fundamentals].
    Piriou V; Aouifi A; Lehot JJ
    Can J Anaesth; 2000 Jul; 47(7):653-63. PubMed ID: 10930206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic potential of third-generation beta-adrenergic receptor blockers. Satellite symposium to the Xth Congress of the European Society of Cardiology. Vienna, Austria, August 31, 1988.
    J Cardiovasc Pharmacol; 1989; 14 Suppl 7():S1-44. PubMed ID: 2481784
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.